Contact Us

Pipeline

Solid pipeline, track record of government grants
OVM-200
OVM-100
OVM-400

Pipeline

Solid pipeline, track record of government grants
OVM-200
OVM-100
OVM-400
Future developments and research being explored incl mRNA delivery

Clinical and Development Assets

OVM 2025 Pipeline

Timelines and strategies under constant review.

Oxford Vacmedix UK

Pipeline Notes:

The graphic above shows the research and development plans for Oxford Vacmedix UK.

For more information, please contact us using the contact form on this website.

OVM-200

OVM-200 Phase 1b is supported by an Innovate UK grant. OVM-200 is a cancer vaccine targeting survivin (inhibitor of apoptosis protein) over expressed in most solid tumours including lung, breast, prostate and ovarian cancers.

OVM-100

OVM-100 is a cancer vaccine targeting HPV related tumours such as cervical cancer and head and neck cancer.

OVM-200 and OVM-100

Clinical trials to have arms for monotherapy and combo therapy.

OVM-400

OVM-400 is an ROP vaccine targeting pancreatic cancer, driven by mutations of the K-RAS gene.
en_GBEnglish
en_GBEnglish